Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Phytogenic Antineoplastic Agents. Found 18 abstracts

Aaron H, Azadarmaki R, Lango MN. Unilateral Vocal Cord Motion Impairment After 1 Dose of Vincristine: Case Report and Literature Review. Am J Ther. 2016 Mar;23(2):e621-3.
Skala E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokinska H, Sliwinski T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. The Journal of pharmacy and pharmacology. 2016 Nov;68(11):1454-64.
Rapoport N, Gupta R, Kim YS, O'Neill BE. Polymeric micelles and nanoemulsions as tumor-targeted drug carriers: Insight through intravital imaging. J Control Release. 2015 May 28;206:153-60.
Jacobs JD, Hopper-Borge EA. Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice. Journal of visualized experiments : JoVE. 2014 Oct 27;92(92):e51917.   PMCID: 4353391
Teijaro CN, Munagala S, Zhao S, Sirasani G, Kokkonda P, Malofeeva EV, Hopper-Borge E, Andrade RB. Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump. Journal of medicinal chemistry. 2014 Dec 26;57(24):10383-90.   PMCID: PMC4281106
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001 Sep;51(1):113-9.
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45.
Bao R, Selvakumaran M, Hamilton TC. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol. 2000 Sep;78(3 Pt 1):373-9.
Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000 Aug;6(8):3071-80.
Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Current oncology reports. 2000 Jan;2(1):76-89.
Langer CJ. Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Invest New Drugs. 2000 Feb;18(1):17-28.
Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. Journal of the National Cancer Institute. 2000 Dec 06;92(23):1934-40.
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000 Oct;60(19):5390-4.
Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999 Jan;58 Suppl 3:43-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Phytogenic Antineoplastic Agents

Phytogenic Antineoplastic Agents drug therapy Human Paclitaxel Female metabolism administration & dosage therapeutic use Antineoplastic Combined Chemotherapy Protocols pharmacology genetics Adult Non-US Gov't Support Antineoplastic Agents US Gov't Support-PHS Middle Age Male Aged Lung Neoplasms drug effects Non-Small-Cell Lung Carcinoma Cultured Tumor Cells Cisplatin Ovarian Neoplasms pathology Clinical Trials Etoposide Survival Analysis Animal Enzyme Inhibitors Drug Administration Schedule Proto-Oncogene Proteins c-bcl-2 Neoplasm Drug Resistance Camptothecin analogs & derivatives Mice Treatment Outcome Antitumor Drug Screening Assays Signal Transduction physiology Drug Dose-Response Relationship Multiple Drug Resistance pharmacokinetics Anthracycline Antibiotics Glioma Phytogenic) 0 (Antineoplastic Agents biosynthesis Polymers methods Apoptosis enzymology Cyclins chemistry Neoplasms Doxorubicin Oral Administration Adjuvant Radiotherapy Neoplasm Proteins Cell Proliferation Transfection adverse effects radiotherapy blood Deoxycytidine antagonists & inhibitors Antineoplastic Antimetabolites aa [Analogs & Derivatives] pd [Pharmacology] 0 (Proto-Oncogene Proteins c-bcl-2) Biological Response Modifiers P-Glycoproteins Alkaloids SCID Mice Bone Neoplasms Glioblastoma Proto-Oncogene Proteins X-Ray Computed Tomography Terpenes human) EC 3-6-1 (PMS2 protein Molecular Cloning bcl-2-Associated X Protein EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) Complementary DNA 85622-93-1 (temozolomide) Small Cell Carcinoma Strychnos Alkylating) 0 (Antineoplastic Agents 0 (Taxoids) 0 (Cyclins) Enzyme Activation Protein p53 Age Factors 3T3 Cells Western Blotting 33419-42-0 (Etoposide) Ewing Sarcoma Rhaponticum carthamoides 33069-62-4 (Paclitaxel) Drug Delivery Systems Optical Imaging 23214-92-8 (Doxorubicin) Antisense Oligodeoxyribonucleotides Medicinal Plants mammalian) 0 (MLH1 protein 4342-03-4 (Dacarbazine) Hydrocortisone Cell Cycle Checkpoints microbiology Breast Neoplasms Bax Local Neoplasm Recurrence Nanoparticle extravasation Agrobacterium Immunohistochemistry use Mononuclear Leukocytes Magnetic Resonance Imaging Salvage Therapy Proportional Hazards Models Dacarbazine ai [Antagonists & Inhibitors] Taxoids DNA Repair Enzymes 951-77-9 (Deoxycytidine) Antineoplastic) 0 (Antimetabolites Animal Models Prostatic Neoplasms Nude Mice Drug Interactions Carrier Proteins Acrylates Intravital microscopy Palliative Care DNA-Binding Proteins Reverse Transcriptase Polymerase Chain Reaction Intra-Arterial Infusions Multidrug Resistance-Associated Proteins Nanoparticles 0 (Neoplasm Proteins) Drug Carriers EC 6-5-1 (DNA Repair Enzymes) therapeutic adverse Mitoxantrone Feasibility Studies Adenosinetriphosphatase Brain Neoplasms Bacterial Transformation Nanodroplets Vocal Cord Paralysis
Last updated on Wednesday, August 12, 2020